Protection against β-amyloid induced abnormal synaptic function and cell death by Ginkgolide J

Neurobiology of Aging

Volumn 30, Issue 2, 2009, Pages 257-265

  Vitolo, Ottavio ^a   Gong, Bing ^a   Cao, Zixuan ^a   Ishii, Hideki ^b   Jaracz, Stanislav ^b   Nakanishi, Koji ^b   Arancio, Ottavio ^a   Dzyuba, Sergei V ^b   Lefort, Roger ^a   Shelanski, Michael ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Amyloid beta; Cell death; Gingko biloba; Long term potentiation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOGINKGO 7/27; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; HIPPOCAMPUS; LONG TERM POTENTIATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; CELLS, CULTURED; GINKGOLIDES; LACTONES; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 57749117451     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.05.025     Document Type: Article

References (56)

1. Aksenov M., Aksenova M., Butterfield D.A., and Markesbery W.R. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74 6 (2000) 2520-2527
2. Andrieu S., Gillette S., Amouyal K., Nourhashemi F., Reynish E., Ousset P.J., Albarede J.L., Vellas B., and Grandjean H. Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J. Gerontol. 58 4 (2003) 372-377
3. Bartlett H., and Eperjesi F. An ideal ocular nutritional supplement?. Ophthalmic Physiol. Opt. 24 4 (2004) 339-349
4. Bastianetto S., Zheng W.H., and Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J. Neurochem. 74 6 (2000) 2268-2277
5. Bate C., Salmona M., and Williams A. Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42. J. Neuroinflamm. 1 1 (2004) 4
6. Campos-Toimil M., Lugnier C., Droy-Lefaix M.T., and Takeda K. Inhibition of type 4 phosphodiesterase by rolipram and Ginkgo biloba extract (EGb 761) decreases agonist-induced rises in internal calcium in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20 9 (2000) E34-E40
7. Chen Q.S., Kagan B.L., Hirakura Y., and Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J. Neurosci. Res. 60 1 (2000) 65-72
8. Crews Jr. W.D., Harrison D.W., Griffin M.L., Falwell K.D., Crist T., Longest L., Hehemann L., and Rey S.T. The neuropsychological efficacy of ginkgo preparations in healthy and congnitively intact adults. HerbalGram 67 (2005) 43-67
9. Cullen W.K., Suh Y.H., Anwyl R., and Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8 15 (1997) 3213-3217
10. DeKosky S.T., Fitzpatrick A., Ives D.G., Saxton J., Williamson J., Lopez O.L., Burke G., Fried L., Kuller L.H., Robbins J., Tracy R., Woolard N., Dunn L., Kronmal R., Nahin R., and Furberg C. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp. Clin. Trials 27 3 (2006) 238-253
11. Doody R.S., Stevens J.C., Beck C., Dubinsky R.M., Kaye J.A., Gwyther L., Mohs R.C., Thal L.J., Whitehouse P.J., DeKosky S.T., and Cummings J.L. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 9 (2001) 1154-1166
12. Francis P. Targeting cell death in dementia. Alzheimer Dis. Assoc. Disord. 20 2 Suppl. 1 (2006) S3-S7
13. Gertz H.J., and Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr. Pharm. Des. 10 3 (2004) 261-264
14. Gold P.E., Cahill L., and Wenk G.L. The lowdown on Ginkgo biloba. Sci. Am. 288 4 (2003) 86-91
15. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., and Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 114 11 (2004) 1624-1634
16. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., and Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model following rolipram treatment. J. Clin. Invest. 114 (2004) 1624-1634
17. Goslin K., Asmussen H., and Banker G. Rat Hippocampal Neurons in Low Density Culture (1998), MIT Press, Cambridge
18. Ishii H., Dzyuba S.V., and Nakanishi K. Lactone-free ginkgolides via regioselective DIBAL-H reduction. Org. Biomol. Chem. 3 19 (2005) 3471-3472
19. Jaracz S., Malik S., and Nakanishi K. Isolation of ginkgolides A, B, C, J and bilobalide from G. biloba extracts. Phytochemistry 65 21 (2004) 2897-2902
20. Kanowski S., Herrmann W.M., Stephan K., Wierich W., and Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29 2 (1996) 47-56
21. Ko W.C., Shih C.M., Lai Y.H., Chen J.H., and Huang H.L. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem. Pharmacol. 68 10 (2004) 2087-2094
22. Kondratskaya E.L., Pankratov Y.V., Lalo U.V., Chatterjee S.S., and Krishtal O.A. Inhibition of hippocampal LTP by ginkgolide B is mediated by its blocking action on PAF rather than glycine receptors. Neurochem. Int. 44 3 (2004) 171-177
23. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95 11 (1998) 6448-6453
24. Le Bars P.L., Kieser M., and Itil K.Z. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord. 11 4 (2000) 230-237
25. Lee T.F., Chen C.F., and Wang L.C. Effect of ginkgolides on beta-amyloid-suppressed acetylocholine release from rat hippocampal slices. Phytother. Res. 18 7 (2004) 556-560
26. Lichtblau D., Berger J.M., and Nakanishi K. Efficient extraction of ginkgolides and bilobalide from Ginkgo biloba leaves. J. Nat. Prod. 65 10 (2002) 1501-1504
27. Mahady G.B. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J. Cardiovasc. Nurs. 16 4 (2002) 21-32
28. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. (Zurich, Switzerland) 9 1 (1999) 133-146
29. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol. Histopathol. 10 2 (1995) 509-519
30. Mattson M.P., and Chan S.L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J. Mol. Neurosci. 17 2 (2001) 205-224
31. Maurer K., Ihl R., Dierks T., and Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J. Psychiatr. Res. 31 6 (1997) 645-655
32. Mazza M., Capuano A., Bria P., and Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol. 13 9 (2006) 981-985
33. Messina B.A. Herbal supplements: facts and myths-talking to your patients about herbal supplements. J. Perianesth. Nurs. 21 4 (2006) 268-278 (quiz 79-81)
34. Mix J.A., and Crews Jr. W.D. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum. Psychopharmacol. 17 6 (2002) 267-277
35. Montine T.J., Markesbery W.R., Zackert W., Sanchez S.C., Roberts II L.J., and Morrow J.D. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am. J. Pathol. 155 3 (1999) 863-868
36. Nakanishi, K., Jaracz, S., Malik, S., Ishii, H., Dzyuba, S.V. Separation of ginkgolides and bilobalide from Ginkgo biloba using column chromatography. PCT Int. Appl. (2005); CODEN: PIXXD2 WO 2005046829 A2 20050526 CAN 142:487413 AN 2005:451255.
37. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 8 (2001) 759-767
38. Oken B.S., Storzbach D.M., and Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 55 11 (1998) 1409-1415
39. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., and Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21 12 (2001) 4183-4187
40. Rai G.S., Shovlin C., and Wesnes K.A. A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment. Curr. Med. Res. Opin. 12 6 (1991) 350-355
41. Saponara R., and Bosisio E. Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue. J. Nat. Prod. 61 11 (1998) 1386-1387
42. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 5594 (2002) 789-791
43. Shif O., Gillette K., Damkaoutis C.M., Carrano C., Robbins S.J., and Hoffman J.R. Effects of Ginkgo biloba administered after spatial learning on water maze and radial arm maze performance in young adult rats. Pharmacol. Biochem. Behav. 84 1 (2006) 17-25
44. Singer S.J., and Dewji N.N. Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc. Natl. Acad. Sci. U.S.A. 103 5 (2006) 1546-1550
45. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., and Markesbery W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 88 23 (1991) 10540-10543
46. Solomon P.R., Adams F., Silver A., Zimmer J., and DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288 7 (2002) 835-840
47. Stackman R.W., Eckenstein F., Frei B., Kulhanek D., Nowlin J., and Quinn J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp. Neurol. 184 1 (2003) 510-520
48. Stine Jr. W.B., Dahlgren K.N., Krafft G.A., and LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278 13 (2003) 11612-11622
49. Troy C.M., Rabacchi S.A., Friedman W.J., Frappier T.F., Brown K., and Shelanski M.L. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J. Neurosci. 20 4 (2000) 1386-1392
50. Troy C.M., and Shelanski M.L. Caspase-2 redux. Cell Death Differ. 10 1 (2003) 101-107
51. Vellas B., Andrieu S., Ousset P.J., Ouzid M., and Mathiex-Fortunet H. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 67 9 Suppl. 3 (2006) S6-S11
52. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., and Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U.S.A. 99 20 (2002) 13217-13221
53. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 6880 (2002) 535-539
54. Wettstein A. Cholinesterase inhibitors and Gingko extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine 6 6 (2000) 393-401
55. Wu Y., Wu Z., Butko P., Christen Y., Lambert M.P., Klein W.L., Link C.D., and Luo Y. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 26 50 (2006) 13102-13113
56. Yao Z., Drieu K., and Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889 1/2 (2001) 181-190